Mutual Pharma Sanctioned In Sulindac Suit

Law360, New York (November 4, 2009, 5:14 PM EST) -- Mutual Pharmaceutical Co. Inc. will have to produce records related to potential side effects of sulindac and four other drugs for withholding a decade's worth of regulatory reports in a suit alleging its prescription anti-inflammatory drug caused a potentially fatal skin disease.

Judge Joseph N. Laplante of the U.S. District Court for the District of New Hampshire granted sanctions against Mutual on Monday, although he found the drugmaker had acted in good faith and stopped short of awarding all the relief plaintiffs Karen L. Bartlett and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.